Gerard P Barry1, Yinxi Yu2, Gui-Shuang Ying2, Lauren A Tomlinson3, Juliann Lajoie4, Marilyn Fisher5, Gil Binenbaum3. 1. Albany Medical College, Department of Ophthalmology, Albany, New York. Electronic address: barryg@amc.edu. 2. Center for Preventive Ophthalmology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Children's Hospital of Philadelphia, Department of Ophthalmology, Philadelphia, Pennsylvania. 4. Albany Medical College, Department of Ophthalmology, Albany, New York. 5. Albany Medical College, Department of Pediatrics, Albany, New York.
Abstract
PURPOSE: To compare rates of short-term retinal detachment (RD) of infants treated for type 1 retinopathy of prematurity (ROP) with intravitreal anti-vascular endothelial growth factor (VEGF) therapy with infants treated with laser therapy. The choice between these 2 treatments remains controversial. Comparative data are limited and describe re-treatment rates rather than retinal structural outcomes predictive of long-term vision. Anti-vascular endothelial growth factor acts faster than laser therapy, which may be beneficial for more aggressive ROP. DESIGN: Nonrandomized, comparative cohort study. PARTICIPANTS: The study included 1167 eyes of 640 infants treated for type 1 ROP. Among these, 164 eyes received anti-VEGF therapy and 1003 eyes received laser therapy. METHODS: Pretreatment and posttreatment examinations and treatments were completed by ophthalmologists with expertise in ROP. The study was a secondary analysis of data from the retrospective Postnatal Growth and Retinopathy of Prematurity Study (G-ROP) 1 study (2006-2012) and the prospective G-ROP 2 study (2015-2017). MAIN OUTCOME MEASURES: Rate of RD (ROP stages 4A, 4B, or 5) within 8 weeks of initial treatment, an end point predictive of poor long-term vision. The results were stratified by postmenstrual age (PMA) at treatment as occurring before versus at or after 36 weeks and 0 days, because earlier disease may be considered more aggressive. RESULTS: Among 458 eyes treated before PMA 36 weeks and 0 days, the short-term RD rate was higher after laser therapy (29/368 eyes [7.9%]) than after anti-VEGF therapy (0/90 eyes [0%]; P < 0.001). Of 709 eyes treated at or after PMA 36 weeks and 0 days, short-term RD risk did not differ between groups (laser [20/635 eyes], 3.1%; anti-VEGF [1/74 eyes], 1.4%; P = 0.27). CONCLUSIONS: Anti-vascular endothelial growth factor therapy results in better short-term structural outcomes than laser therapy when type 1 ROP is treated before 36 weeks' PMA. After this age, both treatments have very low rates of short-term RD. The faster action of anti-VEGF agents likely is responsible for these findings.
PURPOSE: To compare rates of short-term retinal detachment (RD) of infants treated for type 1 retinopathy of prematurity (ROP) with intravitreal anti-vascular endothelial growth factor (VEGF) therapy with infants treated with laser therapy. The choice between these 2 treatments remains controversial. Comparative data are limited and describe re-treatment rates rather than retinal structural outcomes predictive of long-term vision. Anti-vascular endothelial growth factor acts faster than laser therapy, which may be beneficial for more aggressive ROP. DESIGN: Nonrandomized, comparative cohort study. PARTICIPANTS: The study included 1167 eyes of 640 infants treated for type 1 ROP. Among these, 164 eyes received anti-VEGF therapy and 1003 eyes received laser therapy. METHODS: Pretreatment and posttreatment examinations and treatments were completed by ophthalmologists with expertise in ROP. The study was a secondary analysis of data from the retrospective Postnatal Growth and Retinopathy of Prematurity Study (G-ROP) 1 study (2006-2012) and the prospective G-ROP 2 study (2015-2017). MAIN OUTCOME MEASURES: Rate of RD (ROP stages 4A, 4B, or 5) within 8 weeks of initial treatment, an end point predictive of poor long-term vision. The results were stratified by postmenstrual age (PMA) at treatment as occurring before versus at or after 36 weeks and 0 days, because earlier disease may be considered more aggressive. RESULTS: Among 458 eyes treated before PMA 36 weeks and 0 days, the short-term RD rate was higher after laser therapy (29/368 eyes [7.9%]) than after anti-VEGF therapy (0/90 eyes [0%]; P < 0.001). Of 709 eyes treated at or after PMA 36 weeks and 0 days, short-term RD risk did not differ between groups (laser [20/635 eyes], 3.1%; anti-VEGF [1/74 eyes], 1.4%; P = 0.27). CONCLUSIONS: Anti-vascular endothelial growth factor therapy results in better short-term structural outcomes than laser therapy when type 1 ROP is treated before 36 weeks' PMA. After this age, both treatments have very low rates of short-term RD. The faster action of anti-VEGF agents likely is responsible for these findings.
Authors: Julie Morin; Thuy Mai Luu; Rosanne Superstein; Luis H Ospina; Francine Lefebvre; Marie-Noëlle Simard; Vibhuti Shah; Prakesh S Shah; Edmond N Kelly Journal: Pediatrics Date: 2016-03-17 Impact factor: 7.124
Authors: Laura L Snyder; Jose Maria Garcia-Gonzalez; Michael J Shapiro; Michael P Blair Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2016-03 Impact factor: 1.300
Authors: Gil Binenbaum; Lauren A Tomlinson; Alejandra G de Alba Campomanes; Edward F Bell; Pamela Donohue; David Morrison; Graham E Quinn; Michael X Repka; David Rogers; Michael B Yang; Yinxi Yu; Gui-Shuang Ying Journal: JAMA Ophthalmol Date: 2020-01-01 Impact factor: 7.389
Authors: Michelle T Cabrera; Thomas Chia; David K Wallace; J Niklas Ulrich; Sharon F Freedman; Leona Ding; Kevin R Gertsch Journal: Retin Cases Brief Rep Date: 2021-05-01
Authors: Michael H Zhang; Michael P Blair; Sandra A Ham; Sarah H Rodriguez Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2020-09-01 Impact factor: 1.300